Gilead Sciences, Inc. $GILD Holdings Trimmed by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,167 shares of the biopharmaceutical company’s stock after selling 644 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Gilead Sciences were worth $2,014,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the first quarter valued at about $25,000. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at about $27,000. Finally, Goodman Advisory Group LLC bought a new position in Gilead Sciences during the first quarter valued at about $29,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,500 shares of company stock valued at $7,142,140. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.2%

Shares of Gilead Sciences stock opened at $120.94 on Monday. The stock has a 50-day moving average price of $115.47 and a 200 day moving average price of $111.11. The company has a market cap of $150.06 billion, a P/E ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GILD. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. TD Cowen increased their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. Wolfe Research increased their price target on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, BMO Capital Markets increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.